Early stopping rules in clinical trials based on sequential monitoring of serious adverse events

Medical Decision Making

Volumn 29, Issue 3, 2009, Pages 343-350

  Kramar, A ^a   Bascoul Mollevi, C ^b  

^a CENTRE VAL D AURELLE   (France)

^b NONE

Author keywords

Clinical trials; Early stopping rules; Serious adverse event

Indexed keywords

ADVERSE DRUG REACTION; ALGORITHM; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG TOLERABILITY; DRUG WITHDRAWAL; MAXIMUM TOLERATED DOSE; PRACTICE GUIDELINE; SEQUENTIAL ANALYSIS; SIDE EFFECT; SIMULATION; STATISTICAL ANALYSIS; BAYES THEOREM; HUMAN; MONITORING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SAMPLE SIZE; THERAPY;

BAYES THEOREM; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MONITORING, PHYSIOLOGIC; SAMPLE SIZE; THERAPEUTICS;

EID: 67649195430     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X08327332     Document Type: Article

References (14)

1. EudraVigilance. Detailed Guidance on the European Database of Suspected Unexpected Serious Adverse Reactions. Directive 2001/20/EC L121. London: EudraVigilance ; 2002. p 34-44.
2. O'Quigley J., Shen L. Continual reassessment method: a likelihood approach. Biometrics. 1996 ; 52: 673-84.
3. Kramar A., Potvin D., Hill C. Multi-stage designs for phase II clinical trials. Br J Cancer. 1996 ; 74: 1317-20.
4. Bryant R., Day R. Incorporating toxicity considerations into the design of two-stage phase II trials. Biometrics. 1995 ; 51: 656-64.
5. Goldman A., Hannan P. Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm. Stat Med. 2001 ; 20: 1575-89.
6. Chen C., Chaloner K. A Bayesian stopping rule for a single arm study: with a case study of stem cell transplantation. Stat Med. 2006 ; 25: 2956-66.
7. SeqOne. Sequential stopping boundary program. Available from: URL: http://www.biostat.umn.edu/Projects/bounds
8. Proschan M., Lan G., Wittes J. Statistical Monitoring of Clinical Trial: A Unified Approach. Chapter 9. Berlin: Springer ; 2008.
9. Armitage P., McPherson C., Rowe B. Repeated significance test on accumulating data. J R Stat Soc Ser A. 1969 ; 132: 232-44.
10. Hwang I., Shih W., DeCani J. Group sequential designs using a family of type I error probability spending functions. Stat Med. 1990 ; 9: 1439-45.
11. Pocock S. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977 ; 64: 191-9.
12. O'Brien P., Fleming T. A multiple testing procedure for clinical trials. Biometrics. 1979 ; 35: 549-56.
13. Scharfstein D., Tsiatis A., Robins J. Semiparametric efficiency and its implication on the design and analysis of group sequential studies. J Am Stat Assoc. 1997 ; 92: 1342-50.
14. Pico J., Rosti G., Kramar A., et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol. 2005 ; 16: 1152-9.